A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Sc… (NCT07618767) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia
Taiwan267 participantsStarted 2025-09-30
Plain-language summary
This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data from National Taiwan University Hospital cohort studies. The study will include adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants.
Resting-state functional magnetic resonance imaging (MRI) and structural MRI data will be analyzed to estimate default mode network functional transition indices. These indices will be compared between diagnostic groups and examined in association with social cognitive and psychiatric symptom measures, including the Social Responsiveness Scale (SRS) and the Positive and Negative Syndrome Scale (PANSS) when applicable. No new participants will be recruited, and no intervention will be administered. The study will use previously collected data from 80 adults with autism spectrum disorder, 79 adults with schizophrenia, and 108 healthy controls.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Autism spectrum disorder group: participants with a clinical diagnosis of autism spectrum disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
. Schizophrenia group: participants with a clinical diagnosis of schizophrenia according to DSM-5 criteria.
. Healthy control group: participants without a history of autism spectrum disorder, schizophrenia, or other major psychiatric or neurodevelopmental disorders according to available source cohort records.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Default Mode Network mean functional state transition velocity, DMNμV
Timeframe: Baseline / retrospective assessment from pre-existing resting-state fMRI data